ProShares Ultra NASDAQ Biotechnology
BIB
BIB
28 hedge funds and large institutions have $39.2M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
7% less capital invested
Capital invested by funds: $42.3M → $39.2M (-$3.13M)
73% less call options, than puts
Call options by funds: $8.52M | Put options by funds: $31M
Holders
28
Holding in Top 10
2
Calls
$8.52M
Puts
$31M
Top Buyers
| 1 | +$650K | |
| 2 | +$497K | |
| 3 | +$379K | |
| 4 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
+$367K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$301K |
Top Sellers
| 1 | -$3.58M | |
| 2 | -$3.23M | |
| 3 | -$2.11M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.9M |
| 5 |
Jane Street
New York
|
-$978K |